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Abstract
Objective—We describe the development, implementation, and evaluation of a model to 
preemptively select patients for genotyping based on medication exposure risk.
Study Design and Setting—Using de-identified electronic health records (EHR), we derived a 
prognostic model for the prescription of statins, warfarin, or clopidogrel. The model was 
implemented into a clinical decision support (CDS) tool to recommend preemptive genotyping for 
patients exceeding a prescription risk threshold. We evaluated the rule on an independent 
validation cohort, and on an implementation cohort, representing the population in which the CDS 
tool was deployed.
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Results—The model exhibited moderate discrimination with area under the receiver operator 
characteristic curves ranging from 0.68 to 0.75 at one and two years following index dates. Risk 
estimates tended to underestimate true risk. The cumulative incidences of medication prescriptions 
at one and two years were 0.35 and 0.48, respectively, among 1673 patients flagged by the model. 
The cumulative incidences in the same number of randomly sampled subjects were 0.12 and 0.19, 
and in patients over 50 years with the highest body mass indices, they were 0.22 and 0.34.
Conclusion—We demonstrate that prognostic algorithms can guide preemptive 
pharmacogenetic testing towards those likely to benefit from it.
Keywords
Clopidogrel; Computer Decision Support; Electronic Health Records; Precision Medicine; Statin; 
Warfarin
INTRODUCTION
A growing body of literature relates human genetic variation to drug response. Currently, 
more than 100 drugs have pharmacogenomic (PGx) information that affects prescribing in 
Food and Drug Administration (FDA) labels 1. Such evidence was the impetus behind 
Vanderbilt University Medical Center’s Pharmacogenomic Resource for Enhanced 
Decisions in Care & Treatment (PREDICT) program, a quality improvement initiative 
utilizing preemptive, panel-based genotyping to deliver genotype-tailored prescribing 
guidance at the point of care 2.
Previously, we observed the potential for pharmacogenomic testing efficiency gains by 
using a multiplexed genotyping approach. Such gains are possible due to the sufficiently 
high fraction of patients prescribed multiple PGx medications 3. In a cohort of 53,000 
medical home patients at our institution, we estimated, over a 5 year period, approximately 
65% of patients would be prescribed at least one medication with an FDA PGx label, and 
40% would be prescribed multiple PGx medications. Presently, the panel-based genotyping 
platform used for PREDICT covers 184 functional polymorphisms on 34 genes 2, and 
genetic test results are coupled with computerized decision support (CDS) to guide 
prescribers toward the genetically-tailored medications 4.
Ideally, patients could be prescribed genetically-tailored therapy without delay. Towards this 
aim, we sought a predictive model to identify patients likely to be prescribed a therapy that 
would benefit from preemptively recorded genomic information in the electronic health 
record (EHR). Our model identified subjects who were at high risk for being prescribed a 
statin, clopidogrel, or warfarin (medications implemented in PREDICT) over three years. 
See the Clinical Pharmcogenetics Implementation Consortium5 guidelines and webpage 
(https://www.pharmgkb.org/page/cpic) for our rationale for choosing these medications. We 
implemented the model into a CDS tool that alerted physicians if a patient was at high risk 
for being prescribed one of these medications. In this way, individuals could have genetic 
information embedded in their EHR before a prescribing event occurs and could be directed 
towards modified therapy (if necessary) by appropriate CDS. We then examined the model’s 
performance in two, overlapping validation cohorts by calculating the extent to which the 
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model enriched genotyped patients with those eventually be prescribed one of the 
medications. In this report, we describe our approach to model construction, some 
considerations for CDS implementation, and the model’s performance as an initial approach 
for prospective, personalized medicine.
This work is an initial step towards understanding the challenges, considerations, and 
potential for using readily available EHR data towards model driven CDS systems that guide 
patient treatment.
MATERIALS AND METHODS
We developed a predictive model using training data abstracted from EHRs recorded 
between January 1, 2005 and June 30, 2010. We validated this model in two cohorts of 
patients establishing longitudinal care between July 1, 2010 and March 31, 2013.
Study Cohorts
Training cohort—We selected patient records from the Vanderbilt Synthetic Derivative 
(SD) 6 and restricted the analysis to patients who met a definition for Vanderbilt University 
Medical Center as being their ‘medical home’ (MH) between January 1, 2005 and June 30, 
2010, using the definition of having at least three outpatient clinic visits within a two-year 
timeframe. Eligible clinics included: internal medicine and ten subspecialties: cancer, 
hematology, hypertension, rheumatology, nephrology, cardiology, diabetes, neurology, 
nutrition and pulmonary medicine. To be included, we required a patient age, height, and 
weight to be present in the medical record on or before the MH designation date, as this 
served as a marker of having a visit outside of the acute care clinic. Patients were also 
required to have no evidence of statin, warfarin, and clopidogrel prior to the MH date (via 
either electronic prescribing tools or natural language processing 7) so that the prescriptions 
represented new therapy decisions within the EHR. Patients were then followed until their 
last observation prior to June 30, 2010.
Validation and Implementation cohorts—The validation cohort inclusion criteria 
were identical to the training dataset except that patients must have met MH criteria for the 
first time between July 1, 2010 and March 31, 2013. Patients were then followed until their 
last documented clinical encounter prior to March 31, 2013. The implementation cohort 
inclusion criteria were the same as the validation cohort except at the following clinics: 
internal medicine, cardiology, hypertension, diabetes, anticoagulation, ophthalmology, 
nephrology, renal transplant and urology. While several of the clinics between the validation 
and implementation cohort overlapped, many were different and far more were included in 
the implementation cohort due to ongoing reorganization of clinic services and PREDICT.
Model construction strategy
We constructed a predictive model based on clinical variables that were readily available in 
the EHR and coded in a consistent form so it could be easily deployed in a CDS tool. 
Because follow-up times were variable, we used a Cox proportional hazards regression8 to 
model the time to a statin, clopidogrel, or warfarin prescription from the MH date, and in so 
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doing, we were able to estimate medication exposure risk in the presence of censoring. We 
used the following independent variables: age, gender, BMI, and race, weight, height, and 
chronic medical comorbidities (type 2 diabetes, coronary artery disease, atrial fibrillation, 
hypertension, atherosclerosis, congestive heart failure, previous blood clot, and dialysis). All 
comorbidities were determined based on ICD-9 codes prior to the MH date, and two codes 
instantiated a diagnosis 9. Continuous covariate effects were modeled with restricted cubic 
splines to capture non-linear relationships. To examine internal validity, we used a non-
parametric bootstrap10,11.
Evaluation on validation and implementation datasets
To evaluate model performance, we applied training set model results to baseline data 
(applied once at each patient’s MH date) and longitudinal data (applied at each clinic visit 
when covariate data changed) for the validation and implementation sets. Though the 
training set model was constructed with information available at the MH date (i.e., a static 
model), the longitudinal data reflect implementation in practice where each encounter 
represented an opportunity for genotyping. We used a derived, residual time scale to 
translate the static model results to the dynamic longitudinal data 12,13. See Appendix A.1 
for predicted risk calculations from a Cox model and A.2 for residual time scale 
calculations. Time-dependent, area under the ROC curve, AUROC(t), was used to quantify 
model discrimination, and model calibration was assessed graphically. Analyses were 
performed with the R programming language 14, specifically rms() 15 and survivalROC() 16 
libraries.
Enrichment of the genotyped population
We examined the extent to which a real-time algorithm enriched genotyped patients with 
those eventually prescribed a target medication during follow-up. For the baseline validation 
and implementation data sets, we identified patients that exceeded 40% risk of a target drug 
prescription within three years. For the longitudinal datasets, we identified patients who 
exceeded 40% risk at least once within three years from baseline. The 40% risk target was 
set as the clinical target by the PREDICT team early in the program. We then calculated the 
cumulative incidence of a medication prescription during the two years following the MH 
date to estimate time-specific, positive predictive values (PPVs) through two years 
following the MH date. To capture enrichment, we took the difference between model-based 
PPVs and PPVs based on 1) random sampling and 2) applying a rule that flags those over 50 
years with the highest BMIs. According to the estimated Cox model baseline hazard, 40% 
risk at three years translates to 16.5% and 28% risk at one and two years, respectively.
RESULTS
Demographic and other characteristics of the training, validation, and implementation 
cohorts are shown in Table 1. There were a total of 16020 patients in the training dataset and 
12794, 18950, and 6647 patients in the validation, implementation, and both validation and 
implementation datasets, respectively. Importantly, since there was a longer observation 
period for the training dataset than for the other two datasets, observed follow-up was longer 
(median = 1182 days versus 361 and 316 days) and the probability of being prescribed a 
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target medication during follow-up was higher (23.6% versus 9.6% and 11.5%). Patients in 
the training dataset tended to be older (median=51 years) and to have higher rates type 2 
diabetes (17.8%), coronary artery disease (CAD; 4.3%), and atherosclerosis (8.1%) at 
baseline than those in the other two sets; however, they also had a low rate of atrial 
fibrillation (0.1%), presumably reflecting the fact that patients who had been prescribed 
warfarin by the time of the MH date were not included in analyses. Disease prevalence in 
the validation cohorts increased during the observation time as shown in square brackets. 
For example, in the implementation cohort, we observed 18950 patients at 61847 unique 
opportunities for genotyping. At baseline (end of follow-up), 8.1% (9.8%) had a Type II 
diabetes history.
Figure 1 shows the Kaplan-Meier plots using the baseline data for the three cohorts (left 
panel) and using the longitudinal data for the validation and implementation cohorts (right 
panel). Overall, the implementation cohort was prescribed medications at a higher rate than 
the training and validation cohorts, which is likely explained by including proportionately 
more high-risk clinics (e.g., cardiology). One-year prescription risk estimates were 0.088 
(95% CI: 0.083 – 0.093) for the training set, 0.090 (95% CI: 0.084, 0.096) and 0.118 (95% 
CI: 0.084 – 0.096) for the baseline validation and implementation sets, respectively, and 
0.103 (95% CI: 0.100 – 0.107) and 0.113 (95% CI: 0.110 – 0.116) for the longitudinal 
validation and implementation sets, respectively.
The fitted proportional hazards model from the training dataset is shown in figure 2. 
Covariate risk factors associated with higher rates of medication prescription included: older 
age, higher BMI, male gender, and history of type 2 diabetes, CAD, CHF and dialysis. The 
impact of age and BMI on the rate of medication prescription was clearly non-linear with 
larger effects at lower ages and BMI and much smaller effects at higher ages and BMI. 
Figure 2 also shows variable importance (VI) scores that are defined as the likelihood ratio 
Chi-square statistic minus the degrees of freedom17.
Using a non-parametric bootstrap approach, we observed that the overall AUROC for the 
training dataset model showed no evidence of model over-fitting with the estimated 
optimism being 0.01 and the corrected AUROC being 0.67. Applying the results from the 
training data model to the baseline validation, baseline implementation, longitudinal 
validation and longitudinal implementation datasets, we estimated AUROCs at the one-year 
to be 0.71, 0.75, 0.68, and 0.73, respectively. Figure 3 shows AUROCs as a function of the 
time since the MH date for baseline sets and time since the most recent clinic visit for 
longitudinal sets. Interestingly, the model constructed from the training dataset ordered 
subjects’ risk at least as well in the validation and implementation sets as it did in the 
training set. Thus, for the purposes of discrimination, the model exhibited strong external 
validity. We speculate on explanations in the Discussion.
Figure 4 shows the calibration curves for predicting risk at 365 and 730 days from the MH 
date (baseline data) or the most recent clinic visit (longitudinal data). Using the non-
parametric bootstrap on the training dataset model, we observed high internal validity (black 
lines). One-year model predictions performed reasonably well in the validation cohort; 
however, they were underestimated severely in the implementation cohort. For two-year risk 
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predictions, the training data model underestimated risks in both the validation and 
implementation cohorts.
For PREDICT, we deployed the training set model to flag those who were estimated to have 
at least a 40% risk of being prescribed a target medication within three years via CDS at 
outpatient clinics represented by the implementation set. Figure 5 shows the cumulative 
incidences of PGx medication prescriptions over the time since the MH date for the model-
based rule, for a random sampling rule, and the simple rule of ‘genotype patients who are 
over 50 years with the highest BMIs’. Using the longitudinal data for implemented 
PREDICT clinics (lower left panel), 1673 patients were identified for genotyping using the 
model-based rule. Among those, by one and two years following the MH date, the 
cumulative incidences for medication prescriptions were 0.35 and 0.48. With random 
sampling of the same number of patients, the cumulative incidences were 0.12 and 0.19, and 
flagging the 1673 highest BMIs among those over 50 years of age, yielded cumulative 
incidences of 0.22 and 0.34. In the absence of censoring we would therefore estimate that 
the pool of genotyped patients identified by the model would be enriched by 495 
(~1673*(0.484-0.188)) and 238 (~1673*(0.484-0.342)) compared to random sampling and 
the high age/high BMI rule, respectively. It is worth noting that at one year following the 
MH date, the sensitivity and specificity of the model-based decision rule was estimated to be 
0.23 and 0.93, respectively.
Training model portability
Software packages used for model construction are often different from those used to 
support CDS tools, and all analyses described here were conducted using the R 
programming language 18. Using this software, we were able to obtain and port to the 
implementation team the predicted risk at any timepoint t. However, because CDS does not 
use R and because the log survivor function, log[S(t;X)], contains non-parametric and 
parametric components, real-time standard error calculations were not feasible. 19 As a 
workaround, we fit a linear regression of the estimated value of log[SE{log[S(t;X)]}] on 
covariates X to obtain an easy to port estimate of standard errors. See Appendix for a 
description of our approach to validate this model. As can be seen in Figure 6, the model for 
the standard errors appears to reproduce extremely well with the median R2 across 25 
bootstrap replicates being 0.99. We were therefore able to port a simple standard error 
function that accurately estimates prediction uncertainty in real time.
DISCUSSION
We discussed development and implementation of a statistical model within a CDS tool to 
identify patients likely to receive target medications for prospective genotyping. In 
comparison to a strategy of randomly selecting patients to genotype, use of the predictive 
model was estimated to enrich the pool of 1673 patients identified for genotyping by 495 
patients over the course of two years (in the absence of censoring). Our model also 
outperformed a simpler strategy of using an age and BMI cutoff alone. The model ordered 
patient risk (using AUROC) at least as well in the validation and implementation datasets as 
it did in the training dataset. Though the training data model was well calibrated to the 
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validation cohort at one year from the MH date (baseline analysis) and at one year from the 
most recent clinic visit (longitudinal analysis), it underestimated risk in the validation 
dataset at two years and it severely underestimated risk in the implementation cohort.
We speculate that the increase in AUROCs when applying the training set model to the 
validation and implementation sets was likely due to either of both of: 1) exposure/covariate 
data improving over time with less misclassification and measurement error, and 2) 
physicians unintentionally learning from the CDS tool and being more inclined to prescribed 
one of the medications once the CDS tool flags a patients for genotyping. We also speculate 
that the reason for the substantial underestimation of risk in the implementation cohort is 
due to deployment in specialty clinics where physicians are more inclined to prescribe one 
of the target medications (e.g., cardiology). We did not collect such clinic information at the 
outset of this project.
Given increased financial pressures on medicine, movement to a paradigm of predictive 
medicine may lead to improved outcomes and reduced costs. This project represents not 
only model development, but also its real-world application within an EHR. While 
significant efforts have been made with risk prediction models in research settings, few 
complex models have found their way into the EHR. Pharmacogenomics, genomics, and 
predictive medicine are enabled by EHRs but will likely also require their advancement 20.
The success of the PREDICT model relies on multiplexed genetic testing. Multiplexed, 
prospective testing will unnecessarily genotype some people but will also improve the 
probability that a relevant medication will be prescribed. Reactive single gene testing will 
miss people who could have benefitted from having their genetic data available in the EHR 
at the time of prescribing. It also leads to multiple tests being performed when multiple 
medications are prescribed. Indeed, a recent study within the PREDICT population (which 
includes patients selected by the prognostic algorithm) calculated that the number of total 
tests performed was 35% lower in PREDICT than if patients were reactively genotyped on a 
medication by medication basis 21.
This study has several limitations. We required that patients adhere to our definition of MH 
and have age, height, and weight information, which could inhibit generalizability of the 
results. To enable rapid calculation within a real-time EHR, we derived medication 
exposures and past diagnoses using readily-available EHR data which can suffer from 
missing information 22 and misclassification 23,24. While a growing body of work with 
secondary use of EHR data has shown the value of multimodal algorithms to define 
exposures 25–27, many of these algorithms would not be practical for real-time execution 
within most EHR systems. Additionally, patients included in these analyses may represent a 
sicker population due to the requirement of three outpatient clinic visits in a two-year time 
frame.
The model building and validation approach could have been improved in several ways. For 
example, we constructed a model for being prescribed one of three target medications that 
was dominated by statin prescriptions. Fitting separate models for the three indications and 
then combining risks into a single, weighted risk score to determine whom to genotype is an 
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alternative and more flexible approach. We used baseline data from the training dataset to 
predict risk in the longitudinal datasets. Risk predictions might have been improved if we 
had constructed the training model using longitudinal data. We could improve predictions if 
time trends were captured in the model and if we had used use specialty clinics (e.g., 
cardiology) as risk factors. We may also be able to improve predictions with more complex 
models (random forests), though such models may be challenging to implement within 
EHRs. Finally, it is very likely that the non-informative censoring assumption for the Cox 
model was violated during model construction; however such violations are likely to be 
reflected in validation summary measures.
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Figure 1. 
Medication-free survival: Kaplan-Meier based estimates of medication free survival. The 
left panel corresponds to baseline data obtained at the medical home date. The right panel 
corresponds to longitudinal data where the x-axis is the time since last participating clinic 
visit.
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Figure 2. 
The Cox proportional hazards model estimates from the training dataset based on data from 
2005 to 2010. We include a measure of variable importance (VI) that is defined as the 
likelihood ratio Chi-square statistic minus the degrees of freedom used to estimate the 
variable construct.
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Figure 3. 
Time-dependent AUROC(t) calculated by applying the training data model to the training 
dataset across bootstrap replicates (black line), and the training data model to the baseline 
and longitudinal validation and implementation datasets.
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Figure 4. 
Calibration plots for one- and two-year risk estimates. Estimates were calculated by 
applying the training set model to itself across bootstrap replicates and the resulting training 
set model to the validation and implementation datasets. Modified boxplots highlight the 1st, 
10th, 25th, 50th, 75th, 90th, and 99th percentiles of the predicted risk distributions.
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Figure 5. 
Cumulative proportion of pre-emptively genotyped patients prescribed target medications 
over time since the medical home date.
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Figure 6. 
Calibration plots for log-estimated standard error of the log-survivor function based on 25 
bootstrap replicate. The y-axis shows the log of the estimated standard error from the 
original dataset, and the x-axis shows the bootstrapped based predictions of those values.
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Table 1
Demographics and Patient Medical History for the Training, Validation and Implementation Datasets. 
Continuous variables are reported with the 50th (10th, 90th) percentiles and categorical variables are reported 
with percentages. Values inside square brackets correspond to the longitudinal follow-up data.
Variable Training Validation Implementation
N 16020 12794 [55344] 18950 [61847]
Baseline Age (years) 51 (29, 70) 48 (26, 68) 46 (26, 69)
Male 37.6 38.5 36.9
Race
 Black 13.8 11 10.5
 Other 3.1 4.5 4.8
 White 83.2 84.5 84.7
Baseline BMI (kg/m2) 28 (21, 39) 27 (21, 38) 27 (21, 38)
Follow-up (days) 1182 (148, 1720) 361 (47, 812) 316 (23, 774)
Diagnostic history
 Type II Diabetes 17.8 10.6 [12.8] 8.1 [9.8]
 CAD 4.3 1.3 [2.0] 2.9 [3.9]
 Atrial Fibrillation 0.1 1.4 [2.2] 3.6 [4.5]
 Hypertension 32.7 26.2 [31.9] 32.1 [37.3]
 Atherosclerosis 8.1 2.9 [4.2] 4.5 [6.1]
 Congestive Heart Failure 3.4 2.0 [2.5] 2.4 [3.1]
 Previous Clot 1.0 1.2 [2.2] 0.8 [1.2]
 Dialysis 0.7 0.5 [0.7] 1.3 [1.5]
Prescriptions after medical home date
 Statin 19.4 6.5 8.5
 Warfarin 5.0 3.6 3.7
 Clopidogrel 2.8 2.0 2.4
 Any Medication 23.4 9.6 1.5
All Kruskal –Wallis tests for differences in continuous variables at baseline and Chi-square tests for differences in categorical variables at baseline 
were significant at the 0.05 level, and all but gender and previous clot were significant at the 0.001 level.
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